Recruiting PHASE2/PHASE3 INTERVENTIONAL NCT00346814

Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome

Sponsor: Asociación para Evitar la Ceguera en México

Updated 6 times since 2017 Last updated: Jul 30, 2024 Started: Jul 31, 2007 Primary completion: Jul 31, 2007 Completion: Nov 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00346814, this PHASE2/PHASE3 trial focuses on Retinopathy of Prematurity and remains actively recruiting participants. Sponsored by Asociación para Evitar la Ceguera en México, it has been updated 6 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE2/PHASE3
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE2/PHASE3

Status: Unknown → Recruiting
Jul 2024 — Aug 2024 [monthly]

Unknown PHASE2/PHASE3

Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2_PHASE3

First recorded

Jul 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Asociación para Evitar la Ceguera en México

Data source: Asociación para Evitar la Ceguera en México

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Mexico City, Mexico